Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye and ear tests may predict psychosis risk

NCT ID NCT07446569

Knowledge-focused Sponsor: Centre Psychothérapique de Nancy Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether differences in how people see and hear can serve as early warning signs for psychosis. Researchers will compare young adults at high risk or with first-episode psychosis to healthy controls using visual and auditory tasks, plus retinal recordings. The goal is to find simple, non-invasive markers that could help identify those who might develop psychosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could identify early sensory markers that help predict who is at risk for psychosis, enabling earlier intervention.
What could go wrong
This is an observational study, not a treatment trial. It may not find clear markers, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 294 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 30 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: All groups: * Age between 18 and 30 years * Normal or corrected-to-normal visual acuity * Affiliated with or dependent on a social security health insurance plan * Provided informed consent and co-signed the study consent form with the investigator * Proficient in French Control group (TEM) specific criteria: * No current psychiatric disorder (DSM-IV Axis I), except anxiety disorders * No lifetime history of (hypo)manic episodes or psychotic disorders * No first-degree family history of schizophrenia spectrum disorders * No regular use (more than one month continuously) in the past 6 months of the following medications: benzodiazepines, hypnotics, antidepressants, antipsychotics, mood stabilizers, or psychostimulants Clinical High-Risk (CHR) group specific criteria: -Meet CHR criteria according to CAARMS: Attenuated positive symptoms (APS) below clinical threshold in intensity or frequency OR Brief Limited Intermittent Psychotic Symptoms (SPLI) OR Genetic Risk First-Episode Psychosis (PEP) group specific criteria: -Meet PEP criteria according to CAARMS (psychosis threshold reached) Exclusion criteria: * Pregnant, postpartum, or breastfeeding women * Individuals deprived of liberty by judicial or administrative decision * Individuals in a life-threatening emergency * Adults under legal protection measures * Adults unable to provide consent and not under legal protection * Impairment that makes participation in the study or understanding of information difficult or impossible * Alcohol dependence (AUDIT score ≥12 for men, ≥11 for women) * Current substance use disorder (DAST score \>6) * Cannabis use disorder (CUDIT-R score ≥13) * History of neurological disorders, including progressive neurological disease * Progressive retinal disease * Chronic glaucoma * Ophthalmologic conditions affecting visual acuity * Current eye infection * Hearing disorders affecting auditory acuity Criteria incompatible with the electroretinographic device: * Presence of photosensitive epilepsy * Allergy to components of the electrode gel * Behavioral problems causing extreme agitation or aggression * Eye or surrounding tissue lesions that may come into contact with the device

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Early psychosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Psychotic Disorders schizotypal personality disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Early psychosis Schizophrenia prodromal

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier Alpes-Isère

    Saint-Égrève, 38120, France

  • Centre Hospitalier Le Vinatier

    Bron, 69678, France

  • Centre Hospitalier Universitaire de Saint Etienne

    Saint-Priest-en-Jarez, 42270, France

  • Centre Psychothérapique de Nancy

    Laxou, 54520, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.